Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
Holders of 5% or more of VTGN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Vistagen Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 13G/A | 9.99%4.10M shares | – | May 15, 20261 filing | May 15, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 9.97%3.08M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Commodore Capital LP | 13G/A | 9.90%4.24M shares | 0.00 ppfrom 9.90% | Feb 17, 20262 filings | Aug 14, 2026 | SEC |
| TCG Crossover GP I, LLC | 13G/A | 6.70%2.96M shares | – | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
34 Schedule 13D and 13G filings on Vistagen Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20265:49 PM ET | OrbiMed Advisors LLCand 1 other | 13G/A | 0.00%0 shares | −4.20 ppfrom 4.20%Below 5% | Jun 30, 2026 | SEC |
| Aug 14, 20264:27 PM ET | TCG Crossover GP I, LLCand 4 others | 13G/A | 6.70%2.96M shares | – | Jun 30, 2026 | SEC |
| Aug 14, 20264:04 PM ET | Commodore Capital LPand 3 others | 13G/A | 9.90%4.24M shares | 0.00 ppfrom 9.90% | Jun 30, 2026 | SEC |
| May 15, 20264:26 PM ET | TCG Crossover GP II, LLCand 4 others | 13G/A | 9.99%4.10M shares | – | Mar 31, 2026 | SEC |
| Feb 17, 20266:33 PM ET | OrbiMed Advisors LLCand 1 other | 13G/A | 4.20%1.64M shares | −1.14 ppfrom 5.34%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 20264:26 PM ET | Commodore Capital LPand 3 others | 13G/A | 9.90%4.38M shares | – | Dec 31, 2025 | SEC |
| Feb 17, 20264:16 PM ET | Great Point Partners LLCand 2 others | 13G/A | 4.95%2.06M shares | −1.33 ppfrom 6.28%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 202612:35 PM ET | Janus Henderson Group PLC | 13G/A | 0.00%0 shares | −13.60 ppfrom 13.60%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 202610:02 AM ET | StemPoint Capital LPand 2 others | 13G/A | 1.50%616.7K shares | −6.70 ppfrom 8.20%Below 5% | Dec 31, 2025 | SEC |
| Feb 13, 20265:08 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 4.71%1.95M shares | −5.28 ppfrom 9.99%Below 5% | Dec 31, 2025 | SEC |
| Jan 30, 20262:47 PM ET | Vanguard Group Inc | 13G/A | 4.62%1.82M shares | −0.88 ppfrom 5.50%Below 5% | Dec 31, 2025 | SEC |
| Nov 14, 20256:04 PM ET | OrbiMed Advisors LLCand 1 other | 13G | 5.34%1.64M shares | – | Sep 30, 2025 | SEC |
| Nov 14, 20254:37 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 9.99%3.19M shares | 0.00 ppfrom 9.99% | Sep 30, 2025 | SEC |
| Nov 14, 20253:18 PM ET | Great Point Partners LLCand 2 others | 13G/A | 6.28%2.06M shares | −0.31 ppfrom 6.59% | Sep 30, 2025 | SEC |
| Oct 31, 202511:41 AM ET | Vanguard Group Inc | 13G/A | 5.50%1.69M shares | – | Sep 30, 2025 | SEC |
| Sep 8, 20251:07 PM ET | Janus Henderson Group PLCand 1 other | 13G | 13.60%4.17M shares | New | Aug 29, 2025 | SEC |
| Aug 14, 20255:13 PM ET | Great Point Partners LLCand 2 others | 13G/A | 6.59%2.06M shares | −0.06 ppfrom 6.65% | Jun 30, 2025 | SEC |
| May 15, 20254:48 PM ET | Great Point Partners LLCand 2 others | 13G/A | 6.65%2.06M shares | −0.23 ppfrom 6.88% | Mar 31, 2025 | SEC |
| Feb 14, 20254:40 PM ET | Great Point Partners LLCand 2 others | 13G/A | 6.88%2.06M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20254:28 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.97%3.08M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20251:01 PM ET | StemPoint Capital LPand 2 others | 13G/A | 8.20%2.33M shares | +1.70 ppfrom 6.50% | Dec 31, 2024 | SEC |
| Nov 14, 20244:53 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 9.99%2.83M shares | – | Sep 30, 2024 | SEC |
| Feb 12, 20246:27 PM ET | StemPoint Capital LPand 2 others | 13G | 6.50%1.79M shares | New | Dec 31, 2023 | SEC |
| Feb 15, 2022 | Acuta Capital Partners, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Venrock Healthcare Capital Partners II, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | OrbiMed Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2022 | Franklin Resources Inc | 13GOld format | – | New | – | SEC |
| Apr 29, 2021 | Growth Equity Opportunities 17, LLC | 13D/AOld format | – | – | – | SEC |
| Mar 22, 2021 | Acuta Capital Partners, LLC | 13GOld format | – | – | – | SEC |
| Feb 16, 2021 | Acuta Capital Partners, LLC | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Venrock Healthcare Capital Partners II, L.P. | 13GOld format | – | New | – | SEC |
| Feb 12, 2021 | OrbiMed Advisors LLC | 13GOld format | – | New | – | SEC |
| Jan 22, 2021 | Rosalind Advisors, Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 4, 2021 | Growth Equity Opportunities 17, LLC | 13DOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Vistagen Therapeutics, Inc. shares.
No Form 144 notices for Vistagen Therapeutics, Inc. are on file.